1. A method of treating GIST in a human patient, comprising administering to the patient a person in need of treatment an effective GIST dose of a combination of (a) a c-kit inhibitor and (b) a PI3K inhibitor or FGFR inhibitor, or their corresponding pharmaceutically acceptable salts. A method according to claim 1, wherein imatinib, nilotinib and masitinib, or their corresponding pharmaceutically acceptable salts, are selected as the c-kit inhibitor. A combination comprising for the treatment of GIST, (a) a c-kit inhibitor and (b) a PI3K inhibitor or an FGFR inhibitor, or their corresponding pharmaceutically acceptable salts. 4. The method of claim 1 or 2, or the combination of claim 3, wherein the GIST progresses after imatinib therapy. The method of claim 1 or 2, or the combination of claim 3, wherein the GIST progresses after imatinib and sunitinib therapy. A method according to claim 2, in which imatinib is used in a daily dose of 300 to 600 mg. The method according to any one of paragraphs. 1 or 2, or the combination of claim 3, wherein 2-methyl-2- [4- (3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo [ 4,5-c] quinolin-1-yl) phenyl] propionitrile, 5- (2,6-di-morpholin-4-yl-pyrimidin-4-yl) -4-trifluoromethyl-pyridin-2-ylamine and 2-amide 1 - ({4-methyl-5- [2- (2,2,2-trifluoro-1,1-dimethyl-ethyl) -pyridin-4-yl] thiazol-2-yl} -amide) (S) -pyrrolidine-1,2-dicarboxylic acid or their corresponding pharmaceutically acceptable salts.1. Способ лечения GIST у пациента человека, включающий введение пациенту человеку, нуждающемуся в лечении, эффективной в отношении GIST дозы сочетания (a) ингибитора c-kit и (b) ингибитора PI3K или ингибитора FGFR, или их соответствующих фармацевтически приемлемых солей.2. Способ по п. 1, в котором в качестве ингибитора c-kit выбирают иматиниб, нилотиниб и маситиниб, или их соответствующие фармацевтически приемлемые соли.3. Комбинация, включающая для лечения GIST, (a) ингибитор c-kit и (b) ингибитор PI3K или ингибитор FGFR, или их соответ
